<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520792</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0101</org_study_id>
    <nct_id>NCT01520792</nct_id>
  </id_info>
  <brief_title>Paracetamol and Pharmacogenetic</brief_title>
  <official_title>Paracétamol and Pharmacogenetic in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent works has emphasized that the mechanism of action of paracetamol analgesic depend on&#xD;
      its metabolism in the body, since a breakdown product of paracetamol, the AM404 is now&#xD;
      considered the analgesic metabolite of paracetamol suggesting as paracetamol may be a&#xD;
      pro-drug.&#xD;
&#xD;
      Indeed, it has been shown that paracetamol may have a deleterious effect, especially in&#xD;
      vulnerable populations (hepatic insufficiency, elderly). First results showed a very&#xD;
      significant decrease in sulfatation and gluthatione and increased phase 1 metabolism of&#xD;
      acetaminophen, which involves enzymes such as cytochrome P450.&#xD;
&#xD;
      Multifactorial causes, combining nutrition (depletion of sulfur amino acids), increased&#xD;
      detoxification of toxic metabolites of paracetamol, stress or trauma are discussed to explain&#xD;
      the results.&#xD;
&#xD;
      Clinical studies showed a great variability of pain assessment by patients and variability in&#xD;
      the metabolic response of paracetamol. Genetic factors probably play a role remains largely&#xD;
      unknown.&#xD;
&#xD;
      The review of the literature on genetic polymorphism shows the involvement of a number of&#xD;
      enzymes that are well known, predominantly on the metabolism of acetaminophen liver, but&#xD;
      without connection with its analgesic effect. This is a critical missing link in the&#xD;
      understanding of the analgesic effect of paracetamol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy&#xD;
      volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo&#xD;
      on two study periods separated by one week.&#xD;
&#xD;
      The evaluation criterion is the difference in areas under the curve of pain thresholds to&#xD;
      thermal and mechanical stimulations test&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between Pharmacogenetic profile and pain threshold</measure>
    <time_frame>until 14 days before the administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures of thermal and mechanical pain thresholds</measure>
    <time_frame>until 1 hour before the administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of blood concentration of gluthatione</measure>
    <time_frame>until 1 hour before administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol (drug)</intervention_name>
    <description>Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.</description>
    <arm_group_label>Paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  Males&#xD;
&#xD;
          -  Aged between 18 and 30 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject without cons-indications of paracetamol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gisèle PICKERING</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacogenetic of paracetamol</keyword>
  <keyword>Pain threshold</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

